Cargando…
Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial
A multicomponent vaccine has been developed to reduce the frequency of acute exacerbations of COPD associated with non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections, containing NTHi (PD and PE-PilA) and Mcat (UspA2) surface proteins. In a randomised, observer-bli...
Autores principales: | De Smedt, Philippe, Leroux-Roels, Geert, Vandermeulen, Corinne, Tasciotti, Annaelisa, Di Maro, Gennaro, Dozot, Marie, Casula, Daniela, Annaratone, Margherita, Riccucci, Daniele, Arora, Ashwani Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600057/ https://www.ncbi.nlm.nih.gov/pubmed/34820619 http://dx.doi.org/10.1016/j.jvacx.2021.100124 |
Ejemplares similares
-
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study
por: Galgani, Ilaria, et al.
Publicado: (2022) -
Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023) -
Moraxella Catarrhalis peritonitis
por: Sadjadi, Seyed-Ali, et al.
Publicado: (2012) -
Moraxella catarrhalis bacteremic pneumonia
por: Anezaki, Hiroki, et al.
Publicado: (2020) -
Innate immune properties of selected human neuropeptides against Moraxella catarrhalis and nontypeable Haemophilus influenzae
por: Augustyniak, Daria, et al.
Publicado: (2012)